Under the terms of the Company's agreement with the Gates Foundation, the Company is required to develop, manufacture and commercialize soluble TCR bispecific therapeutic candidates targeted to mutua…
Under the revised agreement, the Company received a non-refundable payment of $ 5.0 million in exchange for granting Medison exclusive distribution rights in South America.
of net revenue from sale of therapies relating to the sale of KIMMTRAK primarily in the United States and Europe after estimated deductions for rebates, chargebacks and returns, which are recognized …
Immunocore Holdings plc Debt Obligations
Instrument
Description
Confidence
Evidence
IMCR-DEBT
Debt stack $435.7M
90%
Market cache reports total debt of $435.7M.
IMCR-DEBT-10233
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-09-30.
Immunocore Holdings plc Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Immunocore Holdings plc.
Immunocore Holdings plc Ownership
Holder
Name
Confidence
Evidence
IMCR-OWNER-RTW-INVESTMENTS-LP
RTW INVESTMENTS, LP
90%
13F overlay lists RTW INVESTMENTS, LP as top holder; 145 tracked holders.